Physician profile
Gena A Vail
NPI 1649204629
$4,731.74
in general payments reported to CMS, 2019-2025
25 companies · $649 in 2025
The $649 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $818 · 2022: $1,516 · 2023: $1,001 · 2024: $748 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $966.82 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $468.57 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $459.93 | 2021-2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $342.67 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.97 | 2024-2025 | Relistor, Xifaxan |
| Vertex Pharmaceuticals Incorporated | $213.65 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $158.34 | 2022-2024 | |
| Corcept Therapeutics | $128.13 | 2021 | |
| Genentech USA, INC. | $125.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $122.36 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $120.78 | 2023 | Quviviq |
| Lilly USA, LLC | $119.01 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $116.78 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $109.80 | 2023 | Rexulti |
| Viiv Healthcare Company | $93.67 | 2024 | |
| Zimmer Biomet Holdings, INC. | $87.44 | 2023 | Gel-One Cross-Linked Hyaluronate, Comprehensive Shoulder System, Subchondroplasty Knee Kit |
| Sk Life Science, INC. | $83.33 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.00 | 2023 | Lifevest |
| Gilead Sciences, INC. | $69.87 | 2024 | Epclusa |
| Alnylam Pharmaceuticals INC. | $59.44 | 2023 | Amvuttra |
| Janssen Pharmaceuticals, INC | $50.71 | 2022 | |
| Amarin Pharma, INC. | $32.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Vail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.